Alpha 2.0
Login Register
» Authors » M Ignatiadis

M Ignatiadis

Explore the profile of M Ignatiadis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 2063
Followers 0
Related Specialties
Oncology
Neurology
Cell Biology
Top 10 Co-Authors
C Sotiriou
M Piccart
E de Azambuja
R Salgado
F Rothe
E Agostinetto
M Brandao
L Buisseret
A Awada
V Georgoulias
Published In
Ann Oncol
ESMO Open
Oncology
Eur J Neurol
Pathobiology
Affiliations
Soon will be listed here.
Recent Articles
1.
Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial
Caluwe A, Bellal S, Cao K, Peignaux K, Remouchamps V, Baten A, et al.
Radiother Oncol . 2025 Mar; 206:110836. PMID: 40057199
Background And Purpose: The randomized multicentric phase II Neo-CheckRay trial investigated preoperative immune-modulating stereotactic body radiation therapy (iSBRT) 8 Gy x 3 fractions in combination with chemotherapy with or without...
2.
Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?
Agostinetto E, Buisseret L, Salgado R, Kok M, Ignatiadis M
Ann Oncol . 2024 Mar; 35(5):409-411. PMID: 38484973
No abstract available.
3.
Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis
Nader-Marta G, Monteforte M, Agostinetto E, Cinquini M, Martins-Branco D, Langouo M, et al.
ESMO Open . 2024 Mar; 9(3):102390. PMID: 38460249
Background: The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous results from different studies. We aimed to assess...
4.
ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies
Agostinetto E, Ignatiadis M
Ann Oncol . 2023 Nov; 34(11):955-959. PMID: 37996168
No abstract available.
5.
How I treat endocrine-dependent metastatic breast cancer
Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte J, Ignatiadis M, et al.
ESMO Open . 2023 Feb; 8(2):100882. PMID: 36806375
Estrogen receptor-positive (ER+)/HER2-negative (HER2-), the so-called luminal-type breast cancer, is the most frequent subset, accounting for around 70% of all breast cancer cases. Endocrine therapy (ET) combined with cyclin-dependent kinases...
6.
Liquid biopsy accelerates precision medicine
Amato O, Aftimos P, Ignatiadis M
Ann Oncol . 2023 Feb; 34(4):333-335. PMID: 36804455
No abstract available.
7.
Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future
Geukens T, Brandao M, Laenen A, Collignon J, van Marcke C, Louviaux I, et al.
ESMO Open . 2022 Nov; 7(6):100610. PMID: 36356416
Background: Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective efforts, we here present the first...
8.
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study
Agostinetto E, Ignatiadis M
Ann Oncol . 2021 Feb; 32(4):427-430. PMID: 33571637
No abstract available.
9.
Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment?
Brandao M, Coens C, Ignatiadis M
Ann Oncol . 2019 Oct; 30(11):1677-1681. PMID: 31613310
No abstract available.
10.
Predictive factors for cancer-associated thrombosis in a large retrospective single-center study
Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, et al.
Support Care Cancer . 2019 Jan; 27(4):1163-1170. PMID: 30610431
Background: The relationship between cancer and thrombosis has been studied for years, but reliable guidelines for thromboprophylaxis in that situation are still unclear. Methods: We retrospectively reviewed the files of...